Brief: Mustang Bio Expands Into Autoimmune Diseases With CAR T-Cell Therapy Platform

Fortress Biotech

28/03/2024 13:59

March 28 (Reuters) - Mustang Bio:
    * MUSTANG BIO ANNOUNCES VISION FOR CAR T-CELL THERAPY
PLATFORM
EXPANSION INTO AUTOIMMUNE DISEASES
    * MUSTANG BIO: PLANNING FOR PROOF-OF CONCEPT PHASE 1 TRIAL
EVALUATING MB-106 CD20-TARGETED CAR T-CELL THERAPY IN AUTOIMMUNE
DISEASES UNDERWAY
    * MUSTANG BIO: PHASE 1 TRIAL EVALUATING MB-106 CD20-TARGETED
CAR
T-CELL THERAPY EXPECTED TO INITIATE IN Q4
    * MUSTANG BIO INC - PIVOTAL TRIAL FOR WALDENSTROM
MACROGLOBULINEMIA (WM) IS EXPECTED TO INITIATE IN SECOND HALF OF
2024

Source text for Eikon:  ID:nGNX19gG87 

 ((Reuters.Briefs@thomsonreuters.com;))